Verona Pharma plc VRNA NASDAQ

Verona Pharma plc (VRNA) has shown declining revenue growth over the past 3 years, expanding from $40M to $42M (average -99.4%/yr). The company reported a net loss of $173M in its most recent fiscal year, with earnings trending at -73.9%/yr. The net profit margin is -410.2%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 93.9% (high), with a -6.1pp trend over the period. With a $73B market cap and MOAT composite score of 53/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (15/100, Fail) — revenue or earnings are not growing
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 20-year history, the company was profitable in 1 of 20 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (53/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 33/100 with 0/7 criteria passed.